Vanguard Group Inc Silverback Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $4.96 Trillion
  • Q1 2024

A detailed history of Vanguard Group Inc transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,886,455 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,886,455
Previous 2,106,486 37.03%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
N/A
779,969 Added 37.03%
2,886,455 $0
Q4 2023

Feb 14, 2024
SELL
N/A
-14,803 Reduced 0.7%
2,106,486 $0
Q3 2023

Nov 14, 2023
BUY
N/A
276,097 Added 14.96%
2,121,289 $0
Q2 2023

Aug 14, 2023
BUY
N/A
147,555 Added 8.69%
1,845,192 $0
Q1 2023

May 15, 2023
BUY
N/A
9,717 Added 0.58%
1,697,637 $0
Q4 2022

Feb 10, 2023
BUY
$0.0 - $6.07 $0 - $3.65 Million
600,749 Added 55.26%
1,687,920 $0
Q3 2022

Nov 14, 2022
BUY
$3.91 - $5.52 $119,282 - $168,398
30,507 Added 2.89%
1,087,171 $5.74 Million
Q2 2022

Aug 12, 2022
BUY
$2.9 - $4.44 $676,767 - $1.04 Million
233,368 Added 28.35%
1,056,664 $4.48 Million
Q1 2022

May 13, 2022
SELL
$3.51 - $6.74 $1.71 Million - $3.29 Million
-488,370 Reduced 37.23%
823,296 $2.89 Million
Q4 2021

Feb 14, 2022
SELL
$6.03 - $11.67 $2.16 Million - $4.17 Million
-357,428 Reduced 21.41%
1,311,666 $8.74 Million
Q3 2021

Nov 12, 2021
BUY
$9.98 - $35.22 $6.72 Million - $23.7 Million
673,544 Added 67.66%
1,669,094 $16.7 Million
Q2 2021

Aug 13, 2021
BUY
$24.71 - $44.28 $24.6 Million - $44.1 Million
995,550 New
995,550 $30.8 Million

Others Institutions Holding SBTX

# of Institutions
116
Shares Held
47.9M
Call Options Held
442K
Put Options Held
42K
View Full List

About Silverback Therapeutics, Inc.

SBTX Quotes by TradingView
  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email